- Celgene Corporation stock price today and history
Please, Signup (Login) to subscribe or trade (demo)
Celgene Corporation stock price
Celgene Corporation latest news:
BRIEF-Celgene says net pre-tax charge to Q4 earnings estimated to be $300 mln to $500 mln
* Celgene - concluded oct 18 will recognize q4 charge to
earnings related to impairment of about $1,600 million ged-0301
IPR&D asset - sec filing
Celgene shares drop after Crohn's disease drug trials halted
Celgene Corp. shares dropped in the extended session Thursday after the biotech company said it would discontinue two clinical trials for a Crohn's disease treatment and not start a third. Celgene shares fell 6.2% to $127.55 after hours, following a brief halt. Based on an analysis from a data monitoring committee assessing overall benefit and risk, Celgene said it would discontinue a late-stage clinical trial for the drug GED-0301 to treat Crohn's disease along with an extension trial. Crohn's disease is characterized by a chronic inflammation that can run the entirety of the digestive tract. Celgene said it will also not start a third late-stage clinical trial of the drug for Crohn's disease. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Celgene provides update on GED-0301 (mongersen) inflammatory bowel disease program
* Celgene provides update on GED-0301 (mongersen)
inflammatory bowel disease program
Celgene Faces Multiple Clinical Holds From FDA
Biotech stocks surge on Gilead's Kite Pharma acquisition
After news of Gilead Sciences Inc.'s about $11 billion acquisition of Kite Pharma Inc. , Juno Therapeutics Inc. shares surged 16.3%, Bluebird Bio Inc. shares surged 9.7% and Cellectis SA ADR shares surged 11.8% in extremely heavy midday trade Monday. The Kite Pharma acquisition marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T-cell therapy, or CAR-T, which uses a patient's immune T-cells and re-engineers them to better fight cancer. Juno, Bluebird and Cellectis are other biotech companies working in CAR-T. BTIF analyst Dane Leone upgraded Juno on Monday, adding, "we continue to be skeptical of JUNO's current competitive positioning, but upgrade our ranking to Neutral from Sell, as there is not a near term catalyst to offset the positive tailwind for the entire CAR T space." Though there has been speculation about Celgene -- which owns about 10% of Juno's current shares outstanding -- acquiring Juno, "we would be surprised" by a full acquisition, Leone said, since "at this juncture with emerging overlap in Multiple Myeloma and third to market status in CD19 hematological malignancies, we struggle to find a rationale for Celgene wanting to fully own Juno." Kite Pharma shares surged 28% in extremely heavy morning trade. Shares have surged 144% over the last three months, compared with a 1% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Celgene Corp says on August 10, co issued $500 million aggregate principal amount of 2.250% senior notes due 2021
* Celgene Corp - on August 10, 2017, co issued $500 million aggregate
principal amount of 2.250% senior notes due 2021 - SEC filing
Source text - (http://bit.ly/2hNCc4D)
Further company coverage:
BRIEF-Celgene says monthly wholesale acquisition cost of AML treatment Idhifa is $24,872
* Says monthly wholesale acquisition cost of AML treatment
Idhifa is $24,872
Further company coverage:
FDA approves leukemia treatment developed by Celgene, Agios
Aug 1 (Reuters) - The U.S. Food and Drug Administration
(FDA) on Tuesday approved Celgene Corp and Agios
Pharmaceuticals Inc's treatment for acute myeloid
leukemia (AML) patients with a specific genetic mutation.
Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs
The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.
Celgene Corp. to pay $280 million to settle lawsuit alleging it promoted cancer drugs for unapproved uses
Celgene Corp. to pay $280 million to settle lawsuit alleging it promoted cancer drugs for unapproved uses.
Celldex Therapeutics, Inc.CLDX
Cellectar Biosciences, Inc.CLRB
Cellectar Biosciences, Inc.CLRBW
Cellular Biomedicine Group, Inc.CBMG
Celsus Therapeutics PlcCLTX